Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-arm study of NOVOCART Inject plus for knee cartilage defects
2016-002817-22Phase 3Completed
- Sponsor
- TETEC AG
- Start
- Nov 2016
- Modality
- Cell Therapies, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of NOVOCART Inject in cartilage defect of knee and osteochondritis dissecans (OCD), sponsored by TETEC AG. Primary endpoint: KOOS5 responder rate at 24 months. Started Nov 2016; status: completed.
02
Drugs
NOVOCART Inject
03
Conditions
cartilage defect of kneeosteochondritis dissecans (OCD)
Beyond the preview
Go deeper on 2016-002817-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002817-22.